NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
22 Avril 2024 - 12:57PM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare and wound care
products, announces a new and enhanced marketing program that
includes text message communications (SMS) and targeted email
programs aimed at enhancing the Avenova® brand while engaging with
customers to drive online sales of Avenova products. The new and
enhanced programs build upon the Company’s past highly productive
marketing programs through proprietary channels including social
media and email to cost-efficiently enhance customer loyalty and
reach new prospective customers.
“We recently began using text messaging to capitalize on the
breakaway success we’ve seen with email and social media marketing
in driving customer engagement and Avenova sales while managing our
market spend,” said Justin Hall, CEO of NovaBay. “SMS provides an
additional, immediate touchpoint with our customers and we are
encouraged by the strong initial results. We plan to use text
messaging to share exclusive discounts, news and value-add content
such as tips for enhancing eye health that, collectively, will keep
our audience engaged and interacting with the brand. This program
targets our existing, highly loyal customer base to enhance
retention, while also reaching new audiences.
“The new SMS program builds on the incredible success we’ve had
with our email and social media marketing programs to date,” he
added. “In fact, sales of Avenova from our social media channel for
this year’s first quarter increased more than 160% over the
prior-year quarter, and revenue from our email program has been on
a sustained upward trajectory since mid-2023, up more than 360%. To
drive additional engagement, we recently refreshed our email
campaign to include new creative and also added automation to
further engage with current customers while expanding reach to new
audiences.”
About NovaBay Pharmaceuticals, Inc.
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash
Solution is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is available directly to
consumers through online distribution channels such as Amazon.com.
It is clinically proven to kill a broad spectrum of bacteria to
help relieve the symptoms of bacterial dry eye, yet is
non-irritating and completely safe for regular use. NovaBay offers
a full portfolio of scientifically developed products for each step
of the standard dry eye treatment regimen, including the Avenova
Eye Health Support antioxidant-rich oral supplement, Avenova
Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress
to soothe the eyes and the i-Chek by Avenova to monitor physical
eyelid health. The Avenova Allograft, an amniotic tissue
prescription-only product, is available through eyecare
professionals in the United States.
Forward-Looking Statements
This release contains information about management's view of the
Company's future expectations, plans and prospects that constitute
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the fact that they
do not relate strictly to historic or current facts. Such
forward-looking statements are based upon management’s current
expectations, assumptions, estimates, projections and beliefs.
These statements include, but are not limited to, statements
regarding our business strategies, commercial progress, current and
potential future sales channels, and any future revenue, and the
timing of such revenue, that may result from these marketing
efforts, as well as generally the Company’s expected future
financial results. These statements involve risks, uncertainties
and other factors that may cause actual results or achievements to
be materially different and adverse from those expressed in or
implied by these forward-looking statements. Factors that might
cause or contribute to such differences include, but are not
limited to, risks and uncertainties relating to the size of the
potential market for our products, the Company’s products not being
able to penetrate one or more targeted markets and the Company’s
ability to continue as a going concern and revenues (or the
execution on capital raise opportunities) not being sufficient to
meet the Company’s cash needs. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-K/Q
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on X
Connect with NovaBay on LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422751952/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024